Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Electrocardiography, Ambulatory

Electrocardiography, Ambulatory

Ambulatory electrocardiography, a non-invasive technique that allows continuous monitoring of heart activity during normal daily activities.
This approach provides valuable insights into cardiac function, rhythm disturbances, and ischemic events that may not be detected during resting or brief clinical evaluations.
The data collected can help optimize research protocols, enhance reproducibility, and ultimately improve patient care outcomes.

Most cited protocols related to «Electrocardiography, Ambulatory»

1
Assessing Depression and Cardiovascular Risk
The primary goal of the Heart and Soul Study was to determine why depression is associated with an increased risk of cardiovascular events in outpatients with stable coronary heart disease.25 (link) We used administrative databases to identify outpatients with documented coronary artery disease at 2 Department of Veterans Affairs Medical Centers (San Francisco VA Medical Center and the VA Palo Alto Health Care System, California), 1 university medical center (University of California, San Francisco), and 9 public health clinics in the Community Health Network of San Francisco.
Patients were eligible to participate if they had at least 1 of the following: a history of myocardial infarction, angiographic evidence of at least 50% stenosis in 1 or more coronary vessels, prior evidence of exercise-induced ischemia by treadmill or nuclear testing, a history of coronary revascularization, or a diagnosis of coronary artery disease documented by an internist or cardiologist. Between September 11, 2000, and December 20, 2002, a total of 1024 participants were enrolled: 240 from the public health clinics, 346 from the university medical center, and 438 from the VA medical centers.
All participants completed a baseline examination that included an interview, fasting blood draw, psychiatric interview, questionnaire, echocardiogram, exercise treadmill test, 24-hour ambulatory electrocardiogram, and 24-hour urine collection. Of the 1024 participants who completed the baseline examination, we were not able to contact 7 (<1%) during the follow-up period, leaving 1017 for this analysis. Our protocol was approved by the appropriate institutional review boards, and all participants provided written informed consent.
Whooley M.A., de Jonge P., Vittinghoff E., Otte C., Moos R., Carney R.M., Ali S., Dowray S., Na B., Feldman M.D., Schiller N.B, & Browner W.S. (2008). Depressive Symptoms, Health Behaviors, and Risk of Cardiovascular Events in Patients With Coronary Heart Disease. JAMA : the journal of the American Medical Association, 300(20), 2379-2388.
Publication 2008
Angiography BLOOD Cardiologists Coronary Arteriosclerosis Coronary Artery Disease Coronary Vessels Diagnosis Echocardiography Electrocardiography, Ambulatory Ethics Committees, Research Exercise Tests Heart Ischemia Myocardial Infarction Outpatients Patients Stenosis Urine Specimen Collection Veterans
2
Lumacaftor-Ivacaftor Combination in Cystic Fibrosis
The TRAFFIC and TRANSPORT trials were two phase 3, multinational, randomized, double-blind, placebo-controlled, parallel-group studies in which lumacaftor (VX-809, Vertex Pharmaceuticals) was orally administered in combination with ivacaftor (VX-770, Vertex Pharmaceuticals) for 24 weeks; the studies were conducted from April 2013 through April 2014. The study design and methods of data analysis were identical for the two studies, with the exception of the inclusion of ambulatory electrocardiography (TRAFFIC only) and adolescent pharmacokinetic assessments (TRANSPORT only) for a subgroup of patients. The studies were designed to evaluate the efficacy of lumacaftor–ivacaftor in patients with cystic fibrosis who were homozygous for the Phe508del CFTR mutation; the evaluation of safety was a secondary objective. The protocols (available with the full text of this article at NEJM.org) were reviewed and approved by an ethics committee at each of the 187 participating centers; all patients provided written informed consent.
Patients were randomly assigned (in a 1:1:1 ratio) to one of three study groups (Fig. S1 in the Supplementary Appendix, available at NEJM.org): 600 mg of lumacaftor once daily in combination with 250 mg of ivacaftor every 12 hours (LUM [600 mg/day]–IVA), 400 mg of lumacaftor every 12 hours in combination with 250 mg of ivacaftor every 12 hours (LUM [400 mg every 12 hr]–IVA), or lumacaftor-matched placebo every 12 hours in combination with ivacaftor-matched placebo every 12 hours. All regimens were given for 24 weeks. Randomization was stratified according to age (<18 years vs. ≥18 years), sex, and pulmonary function (percentage of predicted forced expiratory volume in 1 second [FEV1] at screening, <70 vs. ≥70).
The sponsor of the studies (Vertex Pharmaceuticals) designed the protocol in collaboration with the authors. Site investigators collected the data, which were analyzed by the sponsor. All the authors had full access to the study data after the study periods were complete and the data were unblinded. The authors vouch for the accuracy and completeness of the data and for the fidelity of this report to the study protocols, which are available at NEJM.org.
Wainwright C.E., Elborn J.S., Ramsey B.W., Marigowda G., Huang X., Cipolli M., Colombo C., Davies J.C., De Boeck K., Flume P.A., Konstan M.W., McColley S.A., McCoy K., McKone E.F., Munck A., Ratjen F., Rowe S.M., Waltz D, & Boyle M.P. (2015). Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. The New England journal of medicine, 373(3), 220-231.
Publication 2015
Adolescent CFTR protein, human Cystic Fibrosis Electrocardiography, Ambulatory Ethics Committees Homozygote ivacaftor ivacaftor - lumacaftor lumacaftor Lung Mutation Patients Pharmaceutical Preparations Placebos Safety Treatment Protocols Volumes, Forced Expiratory VX-770 VX 809
3
Ambulatory ECG Monitoring in the Workplace
The study was performed at the participants' workplace during working hours. In the morning (during the first three hours of their workday), the participants met with the test instructor at their workplace, and the monitors (Actiheart and Holter) were firmly fixed to their chests. The same instructor placed electrodes and monitors on all participants. The recording lasted approximately 24 hours, covering work, leisure time and sleep. Six of the participants were measured twice and two participants once, yielding a total of 14 ambulatory ECG recordings available for analysis. The participants were informed to do their daily activities as usual and they received a diary in which they were asked to register their daily activities during the recording, and they also received an information sheet about the monitors and the recording.
Kristiansen J., Korshøj M., Skotte J.H., Jespersen T., Søgaard K., Mortensen O.S, & Holtermann A. (2011). Comparison of two systems for long-term heart rate variability monitoring in free-living conditions - a pilot study. BioMedical Engineering OnLine, 10, 27.
Publication 2011
Chest Electrocardiography, Ambulatory Sleep
4
Twins' 24-Hour Heart Rate Variability

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Cell Respiration Coffee Electrocardiography, Ambulatory Nervous System, Autonomic physiology Pressoreceptors Rate, Heart Renin-Angiotensin-Aldosterone System Twins
5
Apple Watch Irregular Pulse Notification Study
The study app was used to verify eligibility, obtain participants’ consent, provide study education, and direct participants through the study procedures. After a participant provided consent, the irregular pulse notification algorithm was activated. The study used the Apple Watch photoplethysmography sensor, which used light-emitting and light-sensitive diodes to intermittently and passively measure changes in blood flow while participants were at rest. These signals were used to generate pulse intervals (tachograms) over 1 minute, which were classified as regular or irregular on the basis of the variation in the pulse interval (Fig. S1 in the Supplementary Appendix). Participants were prompted to initiate a telemedicine visit directly from the app. After the initial notification of an irregular pulse, subsequent tachograms and notifications were recorded but were not provided to the participant. The notification feature was active until September 1, 2018.
Study visits were conducted by physicians from a national telehealth servicer (American Well) with the use of a standardized protocol. Participants with urgent symptoms were directed to go to an urgent care clinic or emergency department. Participants whose eligibility was confirmed and whose symptoms were not urgent were mailed an ECG patch (ePatch) to wear for up to 7 days. The ECG patches were returned by mail and initially examined by trained technicians. Participants with serious arrhythmias were contacted immediately and directed to seek urgent medical care. The ECG patch reports were read by two clinicians, and discrepant interpretations were then reconciled by a committee of clinicians coordinated by the Stanford Center for Clinical Research. In addition, 3-minute ECG strips from each patch, time-aligned to sampled tachograms, were separately read by two clinicians, with disagreements resolved by a third clinician and then a committee, if necessary.
Participants were prompted to initiate a second telemedicine visit to discuss the ambulatory ECG findings and were directed to subsequent care. Study-visit physicians did not initiate treatments. Participants who received irregular pulse notifications were asked to complete a survey, included in the study app, 90 days after notification. All enrolled participants, regardless of notification status, were directed to a Web-based end-of-study survey to be completed by January 31, 2019. All adverse events were reviewed by personnel at the study safety monitoring desk at the Stanford Center for Clinical Research.
Perez M.V., Mahaffey K.W., Hedlin H., Rumsfeld J.S., Garcia A., Ferris T., Balasubramanian V., Russo A.M., Rajmane A., Cheung L., Hung G., Lee J., Kowey P., Talati N., Nag D., Gummidipundi S.E., Beatty A., Hills M.T., Desai S., Granger C.B., Desai M, & Turakhia M.P. (2019). Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. The New England journal of medicine, 381(20), 1909-1917.
Publication 2019
Blood Circulation Cardiac Arrhythmia Electrocardiography, Ambulatory Eligibility Determination Enzyme Multiplied Immunoassay Technique Photoplethysmography Physicians Pulse Rate Safety Telemedicine

Most recents protocols related to «Electrocardiography, Ambulatory»

1
Control Group for Atrial Fibrillation Study
This study selected 88 non-AF patients hospitalized in the Affiliated Hospital of Yangzhou University from May 2017 to June 2018 as the control group.
Inclusion criteria: Patients who have not been confirmed as having AF by electrocardiogram or 24-hour ambulatory electrocardiogram since birth, the patients with non-rheumatic valvular heart disease confirmed by echocardiography, and patients born and lived in Yangzhou for a long time who are of Han nationality and have no blood relationship with each other, and those with complete clinical data were included in the study.
Exclusion criteria: Same AF group.
Shen Han Y., Mahamoud Ahmed A., Chao Z., Jun W, & Xiaochen Y. (2023). Association Between rs2200733 Polymorphism of PITX2 Gene and the Risk of Atrial Fibrillation. Anatolian Journal of Cardiology, 27(3), 160-166.
Publication 2023
BLOOD Childbirth Echocardiography Electrocardiography Electrocardiography, Ambulatory Patients Valve Disease, Heart
2
Cardiac Monitoring During Cancer Therapy
The primary endpoints were safety and efficacy. Acute to late myocardial impairment was defined as cardiac dysfunction (systolic and/or diastolic), pericarditis, pericardial effusion, myocardial ischemia, or heart failure. Safety was monitored by having patients visit the Cardiology and Radiation Oncology departments regularly for interviews, physical examinations, vital sign assessment, ICD checks, blood and biochemical data, ECG, high-resolution ambulatory ECG, UCG, and chest CT as appropriate. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.18 The arrhythmia suppression effect was assessed by antitachycardia pacing (ATP) events, ICD shocks, and manual direct current (DC) shocks. The blanking period was set for 90 days, as reported previously.2 (link)–4 (link) (More information about the methods is provided in the Supplementary File.)
Amino M., Kabuki S., Kunieda E., Hashimoto J., Sugawara A., Sakai T., Sakama S., Ayabe K., Ohno Y., Yagishita A., Kobayashi Y., Ikari Y, & Yoshioka K. (2023). Interim Report of a Japanese Phase II Trial for Cardiac Stereotactic Body Radiotherapy in Refractory Ventricular Tachycardia　― Focus on Target Determination ―. Circulation Reports, 5(3), 69-79.
Publication 2023
BLOOD Cardiac Arrhythmia Cardiovascular System Chest Diastole Effusion, Pericardial Electrocardiography, Ambulatory Heart Failure Myocardial Ischemia Myocardium Patients Pericarditis Physical Examination Safety Shock Signs, Vital Systole
3
Commute-Induced Heart Rate Variability
Heart rate
variability (HRV) was monitored before, during, and after the commute
using an ambulatory ECG (Holter) monitor (GE Seer Light or Seer Light
Extend recorders). Measures of HRV were calculated as outlined by
the Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology, and both time (standard
deviation of normal-to-normal intervals [SDNN]; root mean square of
the successive differences [RMSSD]); and frequency domain measures
of HRV (low-frequency spectral power [LF]; high-frequency spectral
power [HF]).17 (link),18 (link) An expert at the Ottawa Heart
Institute conducted all ECG analysis using a GE Healthcare MARS Workstation,
using data collected over 5-min intervals preceding the following
timepoints: the end of the commute (0 min), 45 min after the commute,
and 90 min after the commute.
Mallach G., Shutt R., Thomson E.M., Valcin F., Kulka R, & Weichenthal S. (2023). Randomized Cross-Over Study of In-Vehicle Cabin Air Filtration, Air Pollution Exposure, and Acute Changes to Heart Rate Variability, Saliva Cortisol, and Cognitive Function. Environmental Science & Technology, 57(8), 3238-3247.
Publication 2023
Cardiovascular System Electrocardiography, Ambulatory Europeans Heart Light Plant Roots
4
Screening for Paroxysmal Atrial Fibrillation

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Age Groups Atrial Fibrillation Electrocardiogram Electrocardiography Electrocardiography, Ambulatory Fibrillation, Paroxysmal Atrial Hypersensitivity Patients Sinuses, Nasal
5
Portable 6-Lead mECG Device for Remote Cardiac Monitoring

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Ankle Electrocardiograph Electrocardiography, Ambulatory Ethics Committees, Research Fingers Gels Knee Joint Lower Extremity Medical Devices Muscle Rigidity Neoplasm Metastasis Skin Thumb Touch

Top products related to «Electrocardiography, Ambulatory»

1
Fm 180 by Fukuda Denshi
Sourced in Japan
The FM-180 is a versatile lab equipment product from Fukuda Denshi. It functions as a multi-parameter monitoring device, capable of simultaneously measuring and displaying various physiological parameters.
2
Tr50b by ADInstruments
Sourced in Australia
The TR50B is a high-precision transducer amplifier designed for use with a variety of sensor types. It provides signal conditioning and amplification for accurate measurement and recording of physical parameters. The TR50B features adjustable gain and filtering options to accommodate different sensor requirements.
3
Lifecard cf by Spacelabs
Sourced in United States
The Lifecard CF is a compact, lightweight cardiac monitoring device designed for continuous heart rate and rhythm monitoring. It records electrocardiogram (ECG) data and provides basic functionality for monitoring cardiac activity.
4
Labchart pro software by ADInstruments
Sourced in United States, Australia, New Zealand
LabChart Pro is a data acquisition and analysis software developed by ADInstruments. It enables users to record, visualize, and analyze data from various experimental setups. The software provides a user-friendly interface and a range of tools for data management, signal processing, and presentation.
5
Easytel s eta by EMKA Technologies
The EasyTEL S-ETA is a laboratory equipment product designed for performing diagnostic tests. It is a compact and automated instrument that streamlines the process of analyzing samples. The EasyTEL S-ETA handles the sample preparation, testing, and result reporting, providing efficient and consistent results.
6
Mars ambulatory ecg analysis system by GE Healthcare
The MARS Ambulatory ECG Analysis System is a medical device designed to record and analyze electrocardiogram (ECG) data. It is used for the continuous monitoring of a patient's heart activity during daily activities.
7
Iox v1.0 base software by EMKA Technologies
IOX (v1.0) Base software is a core software package developed by EMKA Technologies. It provides a fundamental platform for managing and controlling various laboratory equipment and instrumentation.
8
Labchart pro by ADInstruments
Sourced in Australia, United States, New Zealand, United Kingdom, Colombia
LabChart Pro is a data acquisition and analysis software designed for scientific research and experimentation. It allows users to record, view, and analyze a wide range of physiological and experimental data from various instruments and sensors. LabChart Pro provides a user-friendly interface and a range of tools for data management, processing, and visualization.
9
Scm 8000 by Fukuda Denshi
Sourced in Japan
The SCM-8000 is a multi-parameter patient monitoring system developed by Fukuda Denshi. It is designed to continuously monitor and display various vital signs of patients in clinical settings. The core function of the SCM-8000 is to provide accurate and reliable real-time data on a patient's physiological conditions, such as heart rate, blood pressure, and respiratory rate.
10
Seer light ambulatory ecg by GE Healthcare
Sourced in United States
The SEER light ambulatory ECG is a portable device designed to record and monitor a patient's heart activity over an extended period of time. It captures the electrical signals generated by the heart, allowing healthcare professionals to analyze the patient's cardiac performance.

More about "Electrocardiography, Ambulatory"

Ambulatory electrocardiography (ECG), also known as Holter monitoring, is a non-invasive technique that allows continuous monitoring of heart activity during normal daily activities.
This approach provides valuable insights into cardiac function, rhythm disturbances, and ischemic events that may not be detected during resting or brief clinical evaluations.
The data collected can help optimize research protocols, enhance reproducibility, and ultimately improve patient care outcomes.
Some key subtopics and related terms in the field of ambulatory ECG include: - Continuous ECG monitoring: Devices like the Lifecard CF, EasyTEL S-ETA, and MARS Ambulatory ECG Analysis System enable uninterrupted heart activity tracking during daily routines. - Data analysis software: LabChart Pro, IOX (v1.0) Base, and SCM-8000 are software tools that help researchers and clinicians analyze the vast amounts of ECG data collected during ambulatory monitoring. - Portable ECG recorders: Compact devices such as the TR50B and SEER light ambulatory ECG allow patients to go about their normal activities while their heart rhythms are recorded. - Cardiac arrhythmia detection: Ambulatory ECG is particularly useful for identifying irregular heartbeats, including atrial fibrillation, that may not be evident during a clinical visit. - Ischemia monitoring: The continuous data provided by ambulatory ECG can reveal episodes of reduced blood flow to the heart, which may be asymptomatic but still important for treatment and management.
By leveraging the insights gained from ambulatory ECG, researchers can optimize their study protocols, enhance the reproducibility of their findings, and ultimately improve patient care outcomes.
PubCompare.ai's AI-driven platform can help locate the best protocols from literature, preprints, and patents, empowering researchers to take their work to the next level.